Emerging retatrutide, a combined-action drug targeting simultaneously GLP-1 and GIP receptors, is generating considerable buzz within the medical community. Initial clinical trials have shown significant decreases in overall mass and advancements in physiological markers for patients with excess weight . Experts believe this ground-breaking approac